SAB Biotherapeutics, Inc. (SABS)
Last updated: 2026-10-22 10:29:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
SAB Biotherapeutics, Inc. (SABS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.83, with a market capitalization of $262.04M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.44 to $5.15. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$262.04M | |
$2.88 | |
$120.90 | |
$1.00 | |
$2.88 | |
353.98K | |
527.73K | |
-- | |
$5.15 | |
$2.44 | |
-- | |
-- |
SAB Biotherapeutics, Inc. (SABS) Pre-Market Stock Price
SAB Biotherapeutics, Inc. (SABS) is trading at $2.91 in pre-market trading as of 2026-10-21 23:31:00, up 1.08% ($0.03) from the previous close of $2.88
Pre-market trading shows how investors are pricing SABS before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
SAB Biotherapeutics, Inc. (SABS) 7-Day Stock Price Change
Over the past seven days, SAB Biotherapeutics, Inc. (SABS) moved from $2.68 to $2.83, representing a gain of 5.41% ($0.15).
The stock traded between $2.44 and $2.99 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 728.18 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
SABS 52-Week Price Position
Position in Range: 14.2%
SABS is currently trading at $2.83, placing it 14.2% of the way from its 52-week low of $2.44 to its 52-week high of $5.15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is SAB Biotherapeutics, Inc. (SABS)?
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
SAB Biotherapeutics, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 86 |
| Exchange | NASDAQ |
| Company Website |
How to Buy SAB Biotherapeutics, Inc. (SABS) Stock on MEXC
Eligible investors can buy real shares of SAB Biotherapeutics, Inc. (SABS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is SAB Biotherapeutics, Inc. (SABS) stock price today?
2.Is SABS stock going up or down today?
3.What is SABS pre-market price?
4.What is SABS after-hours price?
5.Is SABS stock trading now?
6.Where does SABS sit relative to its 52-week high and low?
7.What sector is SAB Biotherapeutics, Inc. in?
8.What is SAB Biotherapeutics, Inc.'s market capitalization and where is it listed?
9.How is SABS valued in terms of P/E ratio and EPS?
10.Does SAB Biotherapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
SABS Stock Calculator
Estimate the value between SABS shares and USD.
SABS Shares to USD
1.00 SABS shares = 2.825 USD
Calculations are estimates based on the latest available price and are for reference only.



